Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.
FDA status
Approved
Approved. Abaloparatide is the active ingredient in Tymlos, FDA-approved for specific osteoporosis indications. Approval is specific to the product, indication, and route.
Drugs@FDA: Tymlos (NDA 208743)By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human RCT. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 5/5. 382 PubMed citations indexed.
Abaloparatide (Tymlos) is a synthetic 34-amino-acid PTHrP analog that acts as a selective parathyroid hormone receptor 1 (PTH1R) agonist, preferentially stabilizing the receptor in a conformation that
What the literature studies
Recovery Research
Evidence tier
Human RCT
Compounding record
Status not verified
Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source not verified; no checked date is assigned.
Carries a boxed warning for osteosarcoma risk (based on rat carcinogenicity data at high ); use is limited to 2 years cumulative lifetime and contraindicated in patients with
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.